Home2020-11-04T16:24:31+01:00

Slide TRANSFORMING
VISION
Creating a world of bionic vision
for those who have lost their sight
Discover the Prima System

ABOUT PIXIUM VISION

PIXIUM VISION harnesses rapid advances in visual processing, micro-electronics, opto-electronics, neurobiology, and intelligent software algorithms to develop Bionic Vision Systems utilizing its competencies in machine brain interface and artificial intelligence.

These Bionic Vision Systems are aimed at compensating for profound vision loss and improving the independence, mobility and quality like for patients suffering with retinal degenerative diseases.

FACE THE FACTS

For society, blindness is a major economic and social issue leading an increase in direct healthcare costs and indirect costs (lost productivity, costs of care by non-professionals). Treatment for blindness represents a major unmet medical need throughout the world.

Treatment for blindness represents a major unmet medical need throughout the world.

0 million
people are visually impaired1
0 million
people suffer from complete blindness1
0 million
people worldwide affected with AMD2
0
plus diagnosed daily with AMD2

There is currently no cure for blind patients and the consequences of blindness to sufferers include:

Risk of Depression

There is a high risk of depression

Tens of Billions

Blindness costs tens of billions of USD in Europe and the USA3

Quality of Life

Deterioration of quality of life with earlier admission to nursing homes and long-term care facilities

Premature Death

There is a two fold increase in the risk of premature death

Sources
1 WHO 2014 Eye Care fact sheet 282 http://www.who.int/blindness
2 Wong, WL et al., Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. The Lancet Global Health
3 NORC University of Chicago – The Economic burden of vision loss and eye disorders 2013 http://www.norc.org/Research/Projects/

INTERNATIONAL TEAM

Pixium Vision is supported by a prestigious scientific advisory board, and partners which are international, multidisciplinary, spanning basic science to medical expertise, and highly recognized and respected in their fields.

RECENT CLINICAL TRIALS

PIXIUM VISION Continues to Evolve

PRIMA-US-FS clinical study in U.S. and PRIMA-FS clinical study in France are two similar feasibility clinical studies to evaluate the Prima System.

PRIMA-FS clinical study in France successfully completed implantation in 5 patients.

– The first results at 6 months from the study in France were reported during the American Academy of Ophthalmology AAO annual meeting held in Chicago in July 2019

– One year follow-up results were announced by the company in July 2019 and have been reported at the Eye and the Chip meeting in Detroit in November 2019

The results observed in the feasibility study make it possible to consider starting a pivotal study which aims to demonstrate the system’s performance.

Learn more

THE PRIMA TECHNOLOGY

RECENT NEWS & PUBLICATIONS

Pixium Vision receives French regulatory authority (ANSM) approval to initiate European PRIMAvera pivotal study of Prima System

November 20th, 2020|News, Press Releases|

STOCK DATA

Ticker: ALPIX

Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles

Go to Top